I was just reading some very interesting news about the new Hair Genesis V for hair loss.
The University of Albany (SUNY) just performed a recent study and included some investigation work into
, and here what they found out, (http://www.ncbi.nlm.nih.gov/pubmed/19692448).
This study clearly demonstrates a compelling link between tissue inflammation and pattern hair loss. Understanding this link shows that the new Hair Genesis V can stop it in it’s tracks.
More specifically, certain molecular markers of inflammatory cytokines, including CCL17, CXCL6 and LTB(4) are associated with pathways involved in inflammation and apoptosis in many tissue and organ systems, including skin and hair follicles.
Previously, we clinically tested liposterolic extract of Serenoa repens (LSESr) and its glycoside, beta-sitosterol, in subjects likewise affected by pattern hair loss and showed a highly positive response to treatment (http://www.ncbi.nlm.nih.gov/pubmed/12006122).
In the most recent investigation, using a well-validated assay representative of hair follicle keratinocytes, specifically, stimulation of cultured human keratinocyte cells in vitro, we measured changes in gene expression of a spectrum of well-known inflammatory markers.
Lipopolysaccharide (LPS) provided an inflammatory stimulus. In particular, we found that the composition effectively suppressed LPS-activated gene expression of chemokines associated with pathways involved in hair loss.
Our data support the hypothesis that the test compound, which subsequently was refined into Generation V Hair Genesis, exhibits anti-inflammatory characteristics in a well-established in vitro assay representing hair follicle keratinocyte gene expression.
These findings suggest that 5-alpha reductase inhibitors combined with blockade of inflammatory processes represents a novel two-pronged approach in the treatment of AGA with improved efficacy over competing modalities.
Hair Genesis V can stop your hair loss and is the only hair loss treatment on the market with this many clinical studies to back it up.